Home > Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR

Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR

Bio-Medicine.Org

SAN DIEGO, May 16, 2011 /PRNewswire/ -- Volcano Corporation
(NASDAQ:
VOLC[1]) today announced its participation in the Paris course for
Revascularization (EuroPCR) from May 17 – 20. Volcano's focus
will be on highlighting the strength of its product portfolio,
which includes innovative devices like the Vascular Imaging Balloon
Catheter (VIBE® RX), and its sponsorship of a symposium that
highlights the use and value of Precision Guided Therapy in
clinical practice today.

"Volcano is excited to share our state-of-the-art intravascular
therapy guidance and optimization solutions at this year's
EuroPCR," commented Scott Huennekens, President and CEO of Volcano.
"Globally, clinicians are pleased about the insight our
technologies provide them so they can more precisely personalize
the treatment of their patients."

Scientific Symposium on Precision Guided Therapy

Volcano is sponsoring a symposium designed to provide real world
experiences and novel techniques from key opinion leaders in
interventional cardiology from France, Poland, Italy, and the UK.
"Precision Guided Therapy: Simple techniques to go beyond
angiography in everyday practice" will take place on Wednesday, May
18th, in Room 352AB in the Palais Des Congres.

Product Innovations

Volcano will feature its suite of precision guided therapy
technologies, which includes integrated cath lab systems, coronary
and peripheral IVUS catheters, and physiology guide wires measuring
both pressure and flow. These products, which are all available for
sale in the U.S. and/or Europe, include:

The PrimeWire PRESTIGE™, the next generation Fractional
Flow Reserve (FFR) wire with a familiar frontline tip, better
torque and more support for challenging lesions;